What's Happening?
Artificial intelligence is beginning to demonstrate measurable efficiency improvements across clinical development, though investors are advised to differentiate between applications already enhancing operational performance and those with unproven transformative
potential. According to L.E.K. Consulting’s Ben Faircloth, Sej Brar, and Andre Valente, AI can help address the pharmaceutical sector's persistent productivity challenges. The opportunity is significant, as clinical development constitutes a substantial portion of pharmaceutical R&D expenditure, trials are becoming more complex, and drugmakers face increasing pressure to efficiently bring new products to market. The focus is shifting from whether AI can be applied to clinical trials to where it can generate measurable value, how quickly it can be deployed at scale, and which participants in the pharmaceutical services value chain will capture the resulting savings. Early returns are most evident in high-volume, rules-based tasks that can be verified by human specialists, such as clinical data management, medical writing, and regulatory documentation. For instance, Pfizer's collaboration with Saama utilized machine learning to identify coding errors and inconsistencies in clinical trial data, reducing a month-long task to approximately one day.
Why It's Important?
The integration of AI in clinical trials is crucial for the U.S. pharmaceutical industry, which faces mounting pressure to improve R&D returns. With an estimated $200 billion-plus in pharmaceutical revenue potentially losing patent protection between 2027 and 2029, established drugmakers urgently need to replenish their pipelines. AI offers a pathway to manage the increasing complexity of trials, which have seen a five- to six-fold increase in data points for phase II and III trials since 2010. By automating routine work and identifying inconsistencies, AI can help clinical teams process information more efficiently, potentially reducing the cost and duration of clinical programs. This could lead to faster drug development and more efficient market entry for new medicines, benefiting pharmaceutical companies by improving their competitive position and ultimately providing patients with new treatments more quickly. However, the financial benefits may not always accrue to the service providers implementing the AI, as customers may expect lower prices if work is completed faster, potentially pressuring margins.
What's Next?
The next phase for AI in clinical trials involves scaling successful pilot programs into repeatable solutions across multiple customers and studies. While early applications in data management and documentation show promise, more transformative uses like AI-driven drug discovery and digital twins are still maturing and lack sufficient evidence of superior success rates or large-scale economic advantages. Regulatory acceptance will play a critical role in the speed of AI deployment, with efforts by the FDA and EMA to clarify expectations for AI use. Pharmaceutical companies must ensure AI-generated outputs are reliable and that adoption does not compromise trial integrity. Data access and privacy requirements, such as GDPR, also pose constraints, particularly for international operations. Service providers are exploring output-based or results-based commercial models to capture more value from efficiency gains, moving away from traditional time-and-materials contracts. The industry will need to focus on demonstrating repeatable gains in established workflows and proving these gains can be scaled to realize the full potential of AI.
Beyond the Headlines
Beyond the immediate efficiency gains, the widespread adoption of AI in clinical trials could trigger significant long-term shifts in the pharmaceutical industry's operational and commercial landscape. Ethically, the reliance on AI for critical decisions in trial design and patient safety raises questions about accountability and the need for robust human oversight. Legally, evolving regulatory frameworks will need to balance innovation with patient protection, particularly as AI systems become more autonomous. Culturally, there may be a shift in the skill sets required for clinical development professionals, emphasizing data science and AI literacy alongside traditional medical expertise. The challenge of data access and interoperability across different healthcare systems and regulatory environments highlights the need for standardized data practices and secure data-sharing protocols. Ultimately, the success of AI will depend not just on technological feasibility but on its ability to integrate seamlessly into existing workflows, gain regulatory confidence, and establish commercial models that fairly distribute the value created.
